Loading clinical trials...

Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B | Clinical Trials | Clareo Health

COMPLETED

Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B

Management of Health-Related Quality of LIfe Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B

NCT03276130•Swedish Orphan Biovitrum

View on ClinicalTrials.gov

Summary

The puropse of this non-interventional register and survey study is to identify the patterns of prescribed pain, anti-depressive and anti-anxiety medication and management of pain, depression and anxiety for people with haemophilia. The study will be conducted in the Nordic countries (Sweden, Norway, Denmark, Finland) and the aim is to cover the entire haemophilia population in the register part of the study.

Eligibility

Age

5 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Part A population will be defined by having:
•at least one health care contact with main diagnosis haemophilia A or haemophilia B, and/or;
•at least one prescription of factor VIII or factor IX concentrates, or;
•bypassing agents used in the treatment of PwH during the inclusion period.
•Part B1 population: Relevant physician at each HTC with direct and frequent patient contact.
•Part B2 population: PwH 5 years or older listed at participating HTCs

Exclusion Criteria

•NA

Locations (5)

Swedish Orphan Biovitrum Research Site

Copenhagen, Denmark

Swedish Orphan Biovitrum Research Site

Helsinki, Finland

Swedish Orphan Biovitrum Research Site

Gothenburg, Sweden

Swedish Orphan Biovitrum Research Site

Malmo, Sweden

Swedish Orphan Biovitrum Research Site

Stockholm, Sweden

Key Dates

Start Date

October 30, 2018

Primary Completion Date

January 30, 2020

Completion Date

January 30, 2020

Last Updated

March 6, 2024

Enrollment

2,300

ACTUAL participants

Conditions

Haemophilia AHaemophilia B

Sponsors

Lead Sponsor

Swedish Orphan Biovitrum

Related Studies

ENROLLING_BY_INVITATION

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

NCT06285071

Haemophilia AHaemophilia B

ENROLLING_BY_INVITATION

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

NCT06831734

Haemophilia A, Haemophilia B

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions